<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225936</url>
  </required_header>
  <id_info>
    <org_study_id>IM025-015</org_study_id>
    <nct_id>NCT04225936</nct_id>
  </id_info>
  <brief_title>A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment</brief_title>
  <official_title>An Open-label, Two-Part, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the effect of liver impairment on the safety
      and pharmacokinetics (PK) of BMS-986263
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 15, 2020</start_date>
  <completion_date type="Anticipated">May 27, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 26, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of components of BMS-986263 for injection (small interfering RNA (siRNA), di retinamide-PEG-di-retinamide (DPD), and S104)</measure>
    <time_frame>Day 1 to Day 31</time_frame>
    <description>S104 = cationic lipid ((2-((2-(dimethylamino)ethyl)thio)acetyl) azanediyl)bis(ethane-2,1-diyl) ditetradecanoate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T)) of components of BMS-986263 for injection (siRNA, DPD, and S104)</measure>
    <time_frame>Day 1 to Day 31</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of components of BMS-986263 for injection (siRNA, DPD, and S104)</measure>
    <time_frame>Day 1 to Day 31</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total body clearance (CL) of components of BMS-986263 for injection (siRNA, DPD, and S104)</measure>
    <time_frame>Day 1 to Day 31</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution (Vz) of components of BMS-986263 for injection (siRNA, DPD, and S104)</measure>
    <time_frame>Day 1 to Day 31</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life (T-Half) of components of BMS-986263 for injection (siRNA, DPD, and S104)</measure>
    <time_frame>Day 1 to Day 31</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 31 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 59 days or up to 30 days after dosing (whichever is longer)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Nonserious AEs: Up to 31 days ; SAEs: Up to 59 days or up to 30 days after dosing (whichever is longer).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormalities in clinical laboratory assessments</measure>
    <time_frame>Up to 59 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with vital sign abnormalities</measure>
    <time_frame>Up to 59 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with 12-lead electrocardiogram (ECG) abnormalities</measure>
    <time_frame>Up to 59 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with physical examination abnormalities</measure>
    <time_frame>Up to 59 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Group A: Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: Severe Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D: Normal Hepatic function (control group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E: Normal Hepatic Function (optional, control group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986263</intervention_name>
    <description>Single Dose</description>
    <arm_group_label>Group A: Mild Hepatic Impairment</arm_group_label>
    <arm_group_label>Group B: Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Group C: Severe Hepatic Impairment</arm_group_label>
    <arm_group_label>Group D: Normal Hepatic function (control group)</arm_group_label>
    <arm_group_label>Group E: Normal Hepatic Function (optional, control group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  BMI ≥ 18 kg/m^2 and weight ≥ 50 kg at screening (BMI = weight [kg]/height [m^2]).

          -  Participants with normal hepatic function as judged by the investigator

          -  Participants with hepatic impairment as judged by the investigator

        Exclusion Criteria:

          -  Clinically relevant abnormal medical history, abnormal findings on physical
             examination, vital signs, ECG, or laboratory tests at screening that the investigator
             judges as likely to interfere with the objectives of the trial or the safety of the
             participant.

          -  Any major surgery within 4 weeks of study drug administration

          -  Previous exposure to BMS-986263

        Other protocol-defined inclusion/exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

